Meribank Biotech Co., Ltd
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was found… Read more
Meribank Biotech Co., Ltd (4724) - Total Assets
Latest total assets as of June 2025: NT$2.83 Billion TWD
Based on the latest financial reports, Meribank Biotech Co., Ltd (4724) holds total assets worth NT$2.83 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Meribank Biotech Co., Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Meribank Biotech Co., Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Meribank Biotech Co., Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Meribank Biotech Co., Ltd's total assets of NT$2.83 Billion consist of 14.7% current assets and 85.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 6.2% |
| Accounts Receivable | NT$163.76 Million | 6.1% |
| Inventory | NT$11.24 Million | 0.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$584.09 Million | 21.8% |
| Goodwill | NT$282.18 Million | 10.5% |
Asset Composition Trend (2019–2024)
This chart illustrates how Meribank Biotech Co., Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Meribank Biotech Co., Ltd's current assets represent 14.7% of total assets in 2024, a decrease from 15.1% in 2019.
- Cash Position: Cash and equivalents constituted 6.2% of total assets in 2024, down from 8.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 21.8% of total assets.
Meribank Biotech Co., Ltd Competitors by Total Assets
Key competitors of Meribank Biotech Co., Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Meribank Biotech Co., Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Meribank Biotech Co., Ltd generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Meribank Biotech Co., Ltd is currently not profitable relative to its asset base.
Meribank Biotech Co., Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 2.68 | 3.60 |
| Quick Ratio | 1.54 | 2.60 | 3.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$130.47 Million | NT$ 224.85 Million | NT$ 283.83 Million |
Meribank Biotech Co., Ltd - Advanced Valuation Insights
This section examines the relationship between Meribank Biotech Co., Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 152.5% |
| Total Assets | NT$2.68 Billion |
| Market Capitalization | $17.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Meribank Biotech Co., Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Meribank Biotech Co., Ltd's assets grew by 152.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Meribank Biotech Co., Ltd (2019–2024)
The table below shows the annual total assets of Meribank Biotech Co., Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.68 Billion | +152.53% |
| 2023-12-31 | NT$1.06 Billion | +25.48% |
| 2022-12-31 | NT$846.33 Million | -10.66% |
| 2021-12-31 | NT$947.32 Million | +29.77% |
| 2020-12-31 | NT$729.97 Million | +5.32% |
| 2019-12-31 | NT$693.07 Million | -- |